Why the study?
Does preoperative evaluation using in vitro bleeding time (IVBT) with the Thrombostat 4000 prevent bleeding complications in patients with thrombocytopenia?
Does preoperative evaluation using in vitro bleeding time (IVBT) with the Thrombostat 4000 prevent bleeding complications in patients with thrombocytopenia?
Preoperative evaluation of primary hemostasis using the Thrombostat 4000 may help guide treatment and prevent bleeding complications in patients with thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May support IVBT-guided preoperative care in thrombocytopenia; leaves open need for randomized confirmation.
It is difficult to estimate the risk of hemorrhage that may follow an invasive or surgical procedure in patients with thrombocytopenia or platelet dysfunction. Conventional functional tests for the evaluation of primary hemostasis have been questioned. We have evaluated the in vitro bleeding time (IVBT) using the Thrombostat 4000 in 25 patients with thrombocytopenia in order to estimate the risk of bleeding following an invasive or surgical procedure. Using the IVBT, it was possible to suggest and evaluate preoperative treatment in order to restore primary hemostasis. All patients studied had their operations without bleeding complications. From these observations we conclude that the IVBT is a convenient and useful tool in the evaluation of primary hemostasis in these patients.
No takes yet. Share an insight, caveat, or question.
Åleskog et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: